๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 19 Shanghai 17 Guangzhou 13 Changsha 12 Fuzhou 11
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing19 Shanghai17 Guangzhou13 Changsha12 Fuzhou11
All 48 locations
Target enrolment
to

Trials with a site in Guangzhou

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
NCT07559929Small Cell Lung Cancer
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1/2
200
Guangzhou
2026-06-01
Recruiting
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
NCT07253142Non Small Cell Lung Cancer, Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 2
120
Hefei, Fu'zhou, Guangzhou, Nanning, Cangzhou, Harbin, Xinxiang, Wuha
2026-02-05
Recruiting
SKB500 Combinations in Patients With Small Cell Lung Cancer
NCT07296809Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
80
Guangzhou
2026-01-30
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146Small-cell Lung Cancer
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Hefei, Fuzhou, Xiamen, Guangzhou, Naning, Heilongjiang, Shijiazhuang, Zhengzhou
2025-11-30
Recruiting
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
NCT07208773Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
260
Guangzhou
2025-10-29
Active, closed
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)
NCT06612151Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
438
Guangzhou
2024-12-17
Active, closed
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
NCT06500026Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
722
Guangzhou
2024-08-07
Recruiting
ARTEMIS-008๏ผšHS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
NCT06498479Small Cell Lung Cancer
Hansoh BioMedical R&D Company
Phase 3
460
Beijing, Harbin, Zhengzhou, Changchun, Shenyang, Jinan, Shanghai, Guangzhou
2024-07-04
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Amgen
Phase 3
563
Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Guilin, Nanning, Cangzhou
2024-06-05
Active, closed
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer
BeiGene
Phase 1
103
Beijing, Guangzhou, Harbin, Changsha, Shenyang, Xi'an
2024-03-11
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Amgen
Phase 3
404
Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yangzhou
2024-02-20
Recruiting
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
NCT07583511Small-cell Lung Cancer
Sun Yat-sen University
Phase 2
90
Guangzhou
2024-02-01
Active, closed
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
NCT05957510Small-cell Lung Cancer
Guangdong Association of Clinical Trials
Phase 2
66
Guangzhou
2023-07-07
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

6 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 13 studies
PhaseStudiesRecruitingShare
Phase 36246.2%
Phase 24330.8%
Phase 1/22115.4%
Phase 1107.7%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
Amgen20
MediLink Therapeutics (Suzhou) Co., Ltd.21
BeiGene10
Guangdong Association of Clinical Trials10
Hangzhou DAC Biotechnology Co., Ltd.10
Hansoh BioMedical R&D Company11
Shanghai Henlius Biotech11
Sichuan Baili Pharmaceutical Co., Ltd.10
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.11
Sun Yat-sen University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.